CytoSorbents Corporation (CTSO) Actualités

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the...

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo...

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the...

Form 8-K - Current report

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the...

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website

PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the...

Form S-3 - Registration statement under Securities Act of 1933

Form 424B5 - Prospectus [Rule 424(b)(5)]